Novo Nordisk invests further in China

Novo NordiskAs the first multinational company to open a research centre in China in 1997, Novo Nordisk now reaffirms its long-term commitment to the country by investing an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing.

The new 12,000m2 centre will make it possible to increase the number of science employees from the current 130 to 200, with extra space available to accommodate additional future growth. With this expansion, Novo Nordisk also fulfils its key strategic objective to ensure the full range of protein research capabilities in China.

"We see the investment in this new R&D facility as a win-win opportunity for both Novo Nordisk and China. Novo Nordisk recognises the strong science being performed in China and we want to bring innovation from Chinese scientists into our company to help tackle the growing burden of diabetes and other chronic diseases throughout the world," says Mads Krogsgaard Thomsen, chief science officer and executive vice president, Novo Nordisk.

The site in Beijing has already contributed significantly to the company's research and development portfolio in both diabetes and biopharmaceutical target disease areas. The new, expanded facility will enable even stronger contributions from the science team in China across the range of Novo Nordisk's protein technology, biology and pharmacology research activities.

Novo Nordisk's global research organisation, including its other sites in Denmark and the US, is set up to facilitate best practice-sharing and scientific sparring between employees at the different locations to ensure the most efficient and successful pipeline innovation and development.

About Novo Nordisk R&D in China
Novo Nordisk was the first international biopharmaceutical company to establish R&D in China in 1997. The previous Novo Nordisk R&D Centre China in Zhongguancun Life Science Park in Beijing was established in 2002, and has evolved into a centre of excellence for Novo Nordisk in molecular biology, protein chemistry and cell biology. Currently, the R&D organisation in China employs around 130 scientists and the new site, located on a 12,000m2 campus in the same science park, will accommodate a doubling of that number with further expansion potential.

About Novo Nordisk in China
China became a Novo Nordisk business region in 2011, and the company has had an affiliate in China since 1994. The headquarters and R&D Centre are located in Beijing, the production site is in Tianjin, and local offices are located in Shanghai, Guangzhou, Shenyang, Wuhan, Jinan, Hangzhou, Chengdu, Hong Kong and Taiwan. Currently, Novo Nordisk employs around 3,000 people in China.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Soy lecithin NSAID combo drug protects against can…

When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSA...

Novartis receives positive CHMP opinion for Aimovi…

Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Aimovig® (erenumab) for t...

FDA takes action against 53 websites marketing una…

The U.S. Food and Drug Administration today announced that it has warned nine online networks, operating a total of 53 websites, that they must stop illegally marketing p...